Polyunsaturated fatty acid lipoxygenase ALOX12 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Polyunsaturated fatty acid lipoxygenase ALOX12 shows approved-linked disease relevance led by rheumatic disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P18054. Start with rheumatic disease, then reuse UniProt P18054 as the stable protein anchor across project notes and exports.
Start with rheumatic disease, then reuse UniProt P18054 as the stable protein anchor across project notes and exports.
Polyunsaturated fatty acid lipoxygenase ALOX12 shows approved-linked disease relevance led by rheumatic disease. 1 linked drug remains visible in the same block.
Start review with rheumatic disease because it currently carries approved-linked support. Linked drugs include BENOXAPROFEN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPolyunsaturated fatty acid lipoxygenase ALOX12
Review this target as Polyunsaturated fatty acid lipoxygenase ALOX12, mapped to UniProt P18054. Sequence length is 663 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Polyunsaturated fatty acid lipoxygenase ALOX12 as ChEMBL target CHEMBL3687, mapped to UniProt P18054. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Polyunsaturated fatty acid lipoxygenase ALOX12 is the right protein anchor across sources, using UniProt P18054 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why rheumatic disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Polyunsaturated fatty acid lipoxygenase ALOX12 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P18054 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Polyunsaturated fatty acid lipoxygenase ALOX12 |
| UniProt Accession | P18054 |
| Component Type | Protein |
| Sequence Length | 663 aa |
Polyunsaturated fatty acid lipoxygenase ALOX12
Review this target as Polyunsaturated fatty acid lipoxygenase ALOX12, mapped to UniProt P18054. Sequence length is 663 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Polyunsaturated fatty acid lipoxygenase ALOX12 shows approved-linked disease relevance led by rheumatic disease.
Start review with rheumatic disease because it currently carries approved-linked support. Linked drugs include BENOXAPROFEN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4869861 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL7660 | 7.0 | IC50 | 100.0 | Preclinical |
| CHEMBL52 | 6.96 | IC50 | 110.0 | Preclinical |
| CHEMBL222808 | 6.82 | IC50 | 150.0 | Preclinical |
| CHEMBL3113197 | 6.8 | IC50 | 160.0 | Preclinical |
| CHEMBL3113193 | 6.75 | IC50 | 180.0 | Preclinical |
| CHEMBL2018876 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL238624 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL3113198 | 6.66 | IC50 | 220.0 | Preclinical |
| CHEMBL3113169 | 6.62 | IC50 | 240.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 46 | 89 | 5.6 |
| assay format | 45 | 115 | 5.7 |
| cell-based format | 4 | 0 | — |
| tissue-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 9 | 3 | 5.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 0 | — |